Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 6, 2008, Pages 1829-1836

  Evenepoel, Píeter ^a   Meijers, Bjorn K I ^a   de Jong, Hylke ^a   Naesens, Maarten ^a   Bammens, Bert ^a   Claes, Kathleen ^a   Kuypers, Dirk ^a   Vanrenterghem, Yves ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CHRONIC DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOPHOSPHATEMIA; KIDNEY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; REMISSION; TIME;

ADULT; AGED; CALCITRIOL; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; HYPOPHOSPHATEMIA; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES; REMISSION, SPONTANEOUS; TIME FACTORS;

EID: 58149327147     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01310308     Document Type: Article

References (34)

1. Levi M: Post-transpiant hypophosphatemia. Kidney Int 59: 2377-2387, 2001
2. Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem. Y: Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 19: 1281-1287, 2004
3. Bhan I., Shah A, Holmes J, Isakova T, Gutierrez O, Burnett S-A, Juppner H, Wolf M: Post-transplant hypophosphatemia: Tertiary 'hyper-phosphatoninism'? Kidney Int 70: 1486-1494, 2006
4. Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y: Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 7: 1193-1200, 2007
5. Ghanekar H, Welch BJ, Moe OW, Sakhaee K: Post-renal transplantation hypophosphatemia: A review and novel insights. Curr Opin Nephrol Hypertens 15: 97-104, 2006
6. Maalouf NM, Shane E: Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab 90: 2456-2465, 2005
7. Nemere I: The ins and outs of phosphate homeostasis. Kidney Int 721: 140-142, 2007
8. Craver L, Marco MP, Martinez I, Rue M, Borras M, Martin ML, Sarro F, Valdivielso JM, Fernandez E: Mineral metabolism parameters throughout chronic kidney disease stages 1-5: Achievement of K/DOQI target ranges. Nephrol Dial Transplant 22: 1171-1176, 2007
9. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005
10. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31-38, 2007
11. Berndt T, Kumar R: Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol 69: 341-359, 2007
12. Liu S, Quarles LD: How fibroblast growth factor 23 works. J Am Soc Nephrol 18: 1637-1674, 2007
13. Shigematsu T, Kazama J, Yamamashita T, Fukumoto S, Hosova T, Gejyo FFM: Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44: 250-256, 2004
14. Djamali A, Samaniego M, Muth B, Muehrer R, Hofmann RM, Pirsch J, Howard A, Mourad G, Becker BN: Medical care of kidney transplant recipients after the first post-transplant year. Clin J Am Soc Nephrol 1: 623-640, 2006
15. Evenepoel P, Vandenbergh B, Naesens M, Bammens B, Claes K, Kuypers D: Parathyroid hormone accentuates hypercalcemia and elevated calcitriol levels in renal transplant recipients in the early posttransplant period. J Am Soc Nephrol 18: 749A [abstract], 2007
16. Ito N, Fukumoto S, Takeuchi Y, Yasuda T, Hasegawa Y, Takemoto F, Tajima T, Dobashi K, Yamazaki Y, Yamashita T, Fujita T: Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 23: 435-440, 2005
17. Bouillon R, Van Herck E, Jans I, Tan BK, Van Baelen H, De Moor P: Two direct (nonchromatographic) assays for 25-hydroxyvitamin D. Clin Chem 30: 1731-1736, 1984
18. Bouillon R, De Moor P, Baggiolini EG, Uskokovic MR: A radioimmunoassay for 1,25-dihydroxycholecalciferol. Clin Chem 26: 562-567, 1980
19. Bouillon R, Coopmans W, Degroote DE, Radoux D, Eliard PH: Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. Clin Chem 36: 271-276, 1990
20. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1-S201, 2003
21. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P: Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 70: 345-350, 2006
22. Bosma RJ, Doorenbos CRC, Stegeman CA, Homan van der Heide JJ, Navis G: Predictive performance of renal function equations in renal transplant recipients: An analysis of patient factors in bias. Am J Transplant 5: 2193-2203, 2005
23. Drueke T, Lacour B: Disorders of calcium, phosphate, and magnesium metabolism. In: Comprehensive Clinical Nephrology, 3rd ed., edited by Feehally J, Floege J, Johnson RJ, Philadelphia, Mosby, 2007, pp 123-140
24. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18: 2601-2608, 2007
25. Parfitt A: Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab 8: 92-112, 1982
26. Liu S, Brown TA, Zhou J, Xiao ZS, Awad H, Guilak F, Quarles LD: Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 16: 1645-1653, 2005
27. Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M: Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 67: 1171-1178, 2005
28. Stubbs J, Liu S, Quarles D: Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 20: 302-308, 2007
29. Emmett M: What does serum fibroblast growth factor 23 do in hemodialysis patients? Kidney Int 73: 3-5, 2008
30. Falkiewicz K, Nahaczewska W, Boratynska H, Owczarek H, Klinger M, Kaminska D, Wozniak M, Szepietowski T, Patrzalek D: Tacrolimus decreases tubular phosphate wasting in renal allograft recipients. Transplant Proc 35: 2213-2215, 2003
31. Moz Y, Levi R, Lavi-Moshayoff V, Cox KB, Molkentin JD, Silver J, Naveh-Many T: Calcineurin A{beta} is central to the expression of the renal type II Na/Pi co-transporter gene and to the regulation of renal phosphate transport. J Am Soc Nephrol 15: 2972-2980, 2004
32. Ambühl PM: Posttransplant metabolic acidosis: A neglected factor in renal transplantation? Curr Opin Nephrol Hypertens 16: 379-387, 2007
33. Holick MF: Vitamin D for health and in chronic kidney disease. Semin Dial 18: 266-275, 2005
34. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS: Vitamin D deficiency and risk of cardiovascular disease. Circulation 117: 503-511, 2008